Significant augmentation of DTYMK expression was observed in 19 cancer types, including bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), and cervical squamous cell carcinoma (CESC) etc. (Figure 1B). Here, DTYMK is linked to bladder transitional cell carcinoma.